MAM
ATOS icon

Martingale Asset Management’s Atossa Therapeutics ATOS Stock Holding History

Martingale Asset Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,892
Closed -$93K – 824
2021
Q3 		$93K Buy
1,892
+420
+29% +$24.4K ﹤0.01% 838
2021
Q2 		$140K Buy
+1,472
New +$77.9K ﹤0.01% 815

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Martingale Asset Management's ATOS Position: Q4 2021 in Review

Martingale Asset Management sold out of Atossa Therapeutics (ATOS) in Q4 2021, closing a stake of 1,892 shares — an estimated $93K sold.

Martingale Asset Management first reported a position in ATOS in Q2 2021 and held it in 2 quarters. The position peaked at $140K in Q2 2021. 91 funds tracked by Wall St. Rank hold ATOS as of Q4 2021.

  • Martingale Asset Management reported no remaining Atossa Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Martingale Asset Management sold 1,892 Atossa Therapeutics shares in Q4 2021, an estimated $93K.
  • Martingale Asset Management first reported a position in Atossa Therapeutics in Q2 2021 and held it in 2 quarters.
  • Martingale Asset Management's Atossa Therapeutics position peaked at $140K in Q2 2021.
  • 91 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2021.

Based on Martingale Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.